NASDAQ:ADVM   Adverum Biotechnologies, Inc
I think it hit the bottom. From this point on, it will most likely move up (considering all the volume going in). Any news catalyst will easily trigger the stock.

About my point about Phase 2 trial issue in an earlier post, any biopharma company has the risk of a failed Phase 2 trials and/or side-effects. That is why they do these trials, not immediately distribute to public. I am optimistic with the company's vision.